Ashwini Devi Balaraman

Ashwini Devi Balaraman

Auto-generated profile, based on publicly available information

Ashwini Devi Balaraman

Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur – 603202, Tamil Nadu, INDIA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2022 in Letters in Drug Design & Discovery
Verified
Journal Article
Closed access
PDF file
PKPraveen Kumar Posa Krishnamoorthy
Praveen Kumar Posa Krishnamoorthy
ABAshwini Devi Balaraman
Ashwini Devi Balaraman
APAnnadurai Priyadharshini
Annadurai Priyadharshini
DSDharani Abirama Sundari Shanmugam
Dharani Abirama Sundari Shanmugam
SMSivanandham Muthukumaran
Sivanandham Muthukumaran
AKAmrutha K
Amrutha K
Objective: Hepatocellular carcinoma (HCC) is a widely occurring cancer ranking second in humans, with an incidence rate of approximately 1.6% per year in India. Experimental analysis of the Boeravinones or the Rotenoids classification of compounds present in the roots of the Boerhaavia diffusa Linn plant has shown a wide range of anti-cancer activity against liver hepatoblastoma.Methods: Boeravinone B (BB) was screened from widely available Boeravinone A-E compounds based on a maximum drug-likeness score using Lipinski’s rule Five. BB was checked for anti-HCC activity by binding with the five receptors of VEGF, EGF, BCl2, Caspase-3 and Caspase-9 when compared with Sorafenib through molecular docking. GROMACS was used for simulating molecular dynamics.Results: BB has shown a negative maximum internal energy score of -8.04, -8.42, -6.66, -8.33 and -7.74 Kcal/mol when compared to Sorafenib’s internal energy score of -6.55, -7.12, -4.05, -5.48 and -6.12 Kcal/mol for VEGFR, EGFR, BCl2, Caspase-3 and Caspase-9 respectively. Simulation using GROMACS has revealed that RMSD results BB forms a more stable complex with the Caspase-3 and EGFR after 19s and 15s of simulation time. RMSF analysis has characterized local changes on 170-190 residues and 860- 900 residues in C-alpha atoms of BB-Caspase-3 and BB-EGFR complexes revealed protein flexibility.Conclusion: MMPBSA score of BB docked Caspase-3 and EGFR complexes were found to be -62.178 and -42.84 KJ/mol

8 April 2025 in Journal of Circadian Rhythms
Verified
Journal Article
Open access
DSDharani Abirama Sundari Shanmugam
Dharani Abirama Sundari Shanmugam
ABAshwini Devi Balaraman
Ashwini Devi Balaraman
AKAbhijit Kar
Abhijit Kar
AFAbishek Franco
Abishek Franco
BBB. Arjun Chandra Balaji
B. Arjun Chandra Balaji
BSB. Shanthi
B. Shanthi
The anterior region of the hypothalamus accommodates a bilateral structure called the suprachiasmatic nucleus (SCN), which controls, modulates, and perpetuates the homeostasis of circadian rhythm and sleep hormone release. These SCN have a predominance over multitudinous peripheral tissues like the uterus, liver, intestine, pancreas, endocrine system, immune system, reproductive system, and cardiovascular system. This peripheral clock acts as a pacemaker for circadian rhythm timing, which regulates crucial metabolic pathways and organizes numerous activities in the female reproductive network of mammals. The circadian CLOCK genes are expressed in various reproductive organs. The CLOCK, BMAL1, CRY, and PER genes harmonize the balance and manifestation of nuclear receptors (NRs) expression, and the other way round, NRs regulate these circadian genes. Several NRs, in particular estrogen, progesterone, androgen, and PPARs, nurture the ovary and uterus. Bidirectional coordination between SCN and NRs maintains the circadian rhythm of the hypothalamic-pituitary-gonadal (HPG) axis of the female reproductive organs.

10 December 2025 in Archives of Gerontology and Geriatrics Plus
Verified
Journal Article
Open access
VGVinoth Kumar Ganesan
Vinoth Kumar Ganesan
RRRallapalli Rajyalakshmi
Rallapalli Rajyalakshmi
KDKumaraswamy Dabburu
Kumaraswamy Dabburu
DSDharani Abirama Sundari Shanmugam
Dharani Abirama Sundari Shanmugam
ABAshwini Devi Balaraman
Ashwini Devi Balaraman

13 May 2026 in Natural Product Research
Verified
Journal Article
Closed access
GRGayathri Ramalingam
Gayathri Ramalingam
ABAshwini Devi Balaraman
Ashwini Devi Balaraman
PSPoojasri Sribal
Poojasri Sribal
MSMeenakumari S
Meenakumari S
ABArjun Chandra Balaji B
Arjun Chandra Balaji B
RGRubalakshmi G
Rubalakshmi G
Corbichonia decumbens is a medicinal plant with limited comprehensive scientific investigation reported to date. The present study evaluated the phytochemical constituents and multifunctional activities of aqueous extract of C. decumbens leaves. In vitro antioxidant scavenging activity was analyzed using DPPH, H2O2, ABTS radical scavenging assays, while anti-inflammatory potential was evaluated by nitric oxide (NO) inhibition assay in RAW 264.7 cell lines, and antidiabetic activity assessed using the dinitrosalicylic acid (DNS) method. In our present study, the aqueous extract of C. decumbens leaves showed significant results in all radical scavenging assays, DPPH (IC50 - 75.38 ± 3.46 μg/mL), H2O2, (IC50 - 82.79 ± 2.24 μg/mL), ABTS (IC50 - 85.07 ± 2.27 μg/mL), NO inhibition (IC50 - 98.42 ± 1.71 μg/mL), and DNS (IC50 - 102.98 ± 3.95 μg/mL) against the control. The MTT assay was employed to study the cytotoxic properties of the extract, in breast cancer cell line (MCF-7), which demonstrated dose and time-dependent cell depletion with an IC50 value of 91.75 ± 0.89 μg/mL and an IC90 value of 209.99 ± 2.30 μg/mL, respectively. The extract revealed multi-target antimicrobial efficacy against eight bacterial and two fungal strains, along with promising antithrombotic potential and the presence of diverse therapeutically bioactive phytochemical constituents.

30 October 2024 in Iraqi Journal of Science
Verified
Journal Article
Open access
PDF file
DSDharani Abirama Sundari Shanmugam
Dharani Abirama Sundari Shanmugam
RCRishi Choudhury
Rishi Choudhury
SJSb Javn
Sb Javn
VGVinoth Kumar Ganesan
Vinoth Kumar Ganesan
MMMagrita Malngiang
Magrita Malngiang
MKMerugumolu Vijay Kumar
Merugumolu Vijay Kumar
The COVID-19 pandemic has clasped the world by furore storm. India has been the epicenter of the surge in COVID cases since March 2021 which is being considered as the second wave. With every passing week, new guidelines were being implemented by various states as well as the central government to control the situation. Hospitals were running out of beds, oxygen, and medicinal supply with patients with comorbidities suffering the most. A handful of drugs have been approved for direct or emergency use to counter the situation. However, over time some of these drugs have faced strong backlash for being ineffective and hence are no longer in use. In this review, we shall study various vaccines that have been approved in India and abroad and, also various drugs which were approved for treating the COVID-19 patients.